A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases

Journal of Infection and Chemotherapy

Volumn 19, Issue 1, 2013, Pages 89-97

  Watanabe, Akira ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Asthma; Influenza (H1N1) 2009; Laninamivir; Neuraminidase inhibitor

Indexed keywords

LANINAMIVIR OCTANOATE; OSELTAMIVIR;

2009 H1N1 INFLUENZA; ADULT; AGED; ARTICLE; ASTHMA; BRONCHITIS; BRONCHOSPASM; CHRONIC RESPIRATORY TRACT DISEASE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFLUENZA; INFLUENZA A (H3N2); JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL HALLUCINATION;

EID: 84874106300     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0460-1     Document Type: Article

References (26)

1. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57:1-60.
2. The City of New York Department of Health and Mental Hygiene. In: New York City Department of Health and Mental Hygiene Health Alert #22: Novel H1N1 Influenza Update June 12, 2009. 2009. http://www.nyc.gov/html/doh/downloads/pdf/ cd/2009/09md22.pdf. Accessed 12 March 2012.
3. Zarychanski R, Stuart TL, Kumar A, Doucette S, Elliott L, Kettner J, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ. 2010;182:257-64.
4. Kumar A. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life. J Antimicrob Chemother. 2011;66:959-63.
5. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361:1935-44.
6. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-24.
7. World Health Organization. Influenza A (H1N1) virus resistance to oseltamivir - 2008/2009 influenza season, northern hemisphere. http://www.who.int/influenza/resources/documents/H1N1webupdate20090318-ed-ns. pdf. Accessed 12 March 2012.
8. Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, et al. Clinical effectiveness of oseltamivir for influenza A (H1N1) virus with H274Y neuraminidase mutation. J Infect. 2009;59:207-12.
9. Centers for Disease Control and Prevention. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:893-6.
10. Graitcer SB, Gubareva L, Kamimoto L, Doshi S, Vandermeer M, Louie J, et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009 - United States. Emerg Infect Dis. 2011;17:255-7.
11. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51:1167-75.
12. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575-82.
13. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009;53:186-92.
14. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460:1021-5.
15. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med. 2000;342:661-2.
16. TM: Summary of product characteristics. Brentford: GlaxoSmithKline; 2011.
17. Behrens B, Kärber G. Wie sind Rehenversuche für biologishe Auswertungen am zweckmäsigsten anzuordnen? (in German). Naunyn Schmiedebergs Arch Pharmakol Exp Pathol. 1935;177:379-88.
18. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235-40.
19. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-24.
20. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845-50 (Erratum, Lancet 2000;356:1856).
21. Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I. Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza - placebo-controlled double-blind multicenter phase III trial (in Japanese). Kansenshogaku Zasshi. 2000;74:1044-61.
22. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline: Statistical principles for clinical trials E9. 1998. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E9/Step4/E9-Guideline.pdf. Accessed 12 March 2012.
23. van den Brand JM, Stittelaar KJ, van Amerongen G, Rimmelzwaan GF, Simon J, de Wit E, et al. Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J Infect Dis. 2010;201:993-9.
24. Kawai N, Hirotsu N, Ikematsu H. Symptoms and complications of influenza. In: The Influenza Study Group of Japan Physicians Association, eds. Clinical practice manual for influenza. 5th edn. Tokyo: Japan Physicians Association; 2010. p. 4-6 (in Japanese).
25. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis. 2003;187:1000-9.
26. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-72.